Laboratorios Clausen
Español
News
Back
 
ELAXIM LAUNCHING
lunes, 22 de agosto de 2011
Laboratorios Clausen S. A. announces the launching of Elaxim (Tenecteplase, recombinant, t-PA).
 
Suprimun, (mycophenolate mofetil) by Laboratorios Clausen S.A. was approved in Europe.
lunes, 29 de noviembre de 2010
Suprimun, (mycophenolate mofetil) by Laboratorios Clausen S.A. was approved in Europe.
 
Agreement between Clausen and the Special Techniques Laboratory
jueves, 25 de marzo de 2010
Laboratorios Clausen S.A. would like to inform the healthcare professionals that we have reached an agreement with our product Kimatinib (Imatinib Mesylate), at the Special Techniques Laboratory of the "Asociación Española Primera de Socorros Mutuos in Montevideo- Uruguay"
 
KIMATINIB LAUNCHING
lunes, 27 de julio de 2009
Laboratorios Clausen SA announces the launch of Kimatinib (Imatinib Mesylate), produced at the plant in High Technology Clausen.
 
Launching of Interferon beta-1 a Clausen
domingo, 31 de mayo de 2009
Laboratorios Clausen S.A announces the launching of Interferón beta-1a Clausen in prefilled syringes 6 and 12 MIU, indicated for the treatment of relapsing-remitting Multiple Sclerosis.
 
Eritrogen: the known formula of human recombinant erythropoietin by Clausen
miércoles, 19 de abril de 2006
Eritrogen, recombinant human erythropoietin manufactured by Clausen, is now available in prefilled syringe containing 10.000 UI in 1 ml of solution.
 
jueves, 02 de febrero de 2006
 
“The European Patent for a Uruguayan Biotechnological Development in the field of Biomedicine was granted”
jueves, 12 de enero de 2006
A protein obtained through an investigational process of the University of the Republic and Laboratorios Clausen S.A. has its own license in Europe
 
Important Information on Thymoglobuline
lunes, 15 de agosto de 2005
Genzyme Polyclonals, S.A.S. wishes to comunicate an important modification on dosage recommendations of Thymoglobuline (anti human thymocite rabbit immunoglobuline), a biological product indicated for the treatment and prevention of acute rejection, prevention of acute and cronic graft versus host disease following bone marrow transplantation and the treatment of graft versus host disease resistent to steroid and aplastic anemia.
 
Presenting: Ciclomun Neo CGB
viernes, 10 de junio de 2005
Laboratorios Clausen S.A. presents Ciclomun Neo CGB (soft gel capsules of cyclosporine emulsion GEDDS).
 
Worshop Transfusional Medicine and Gynecology
viernes, 03 de junio de 2005
Next june 18th 2005 from 9 to 13 hours in San Carlos - Maldonado will take place the first Workshop in Transfusional Medicine and Gynecology
 
Seminar Vaccination at High Risk Patients
lunes, 30 de mayo de 2005
The Seminar will take place april 7 and 8 2005. organized by FUNCEI Uruguay - GROG and the support of Laboratorios Clausen S.A.
 
Efficacious vaccines
martes, 26 de octubre de 2004
The hepatitis A is a viral endemic disease distributed amply by an enterovirus of human reservoir exclusively. Transmission is by fecal material by direct contamination (person to person contact) or indirect contamination (contact with contaminated water or food), this explains the dissemination in variable endemic zones attending the hygiene level and the sanitary conditions.
 
A shared challenge in Biotechnology
viernes, 08 de octubre de 2004
The UCCB creation is framed inside the needed and complementary institutional strategies. In one hand a relationship strategy by the University of the Republic attending the private sector with the intention of development applicable to the reality which could have aftereffect in the productive sector. On the other hand a quality control strategy in a private company - Laboratorios Clausen S.A. – which looks for the technological interchange with the academic sector in order to develop a whole national pharmaceutical production.
 
CLAUSEN AN ENDEAVOR’S ENTREPRENEUR
martes, 14 de septiembre de 2004
The Project Human Recombinant Trombopoyetin is been developed in terms of a entreprise between private industrie and the public University.